Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 2 days agoScore70
Body
APEX-Breast01 Rolditamig DXd (TQB2102, a biparatopic ADC) vs TPC chemo in HER2-low MBC has meaningful efficacy
median PFS 16.4 vs 5.5 mo HR=0.29
OS HR=0.44
ORR 68.8% vs 31.0%
#ESMO26
506 views · 7 likes · 4 reposts · 1 reply
Conference abstracts
LBA27matched by Proffered paper 1: Breast cancer, early and advanced stage
APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study
https://esmocongress.esmo.orgReplies in this thread
- Stephanie Graff, MD, FACP, FASCO@DrSGraff
How to incorporate in complex landscape of ADCs and variability in available treatments internationally remains unclear. #ESMO26
Source: Stephanie Graff, MD, FACP, FASCO · x.com